Osteoporoza - Materijal Za Spremanje Testa

  • Published on
    21-Apr-2015

  • View
    26

  • Download
    5

Embed Size (px)

Transcript

,

, , , , , , , , , , , , . , . - , - , . . . , , , , . . , , , . 50 , . , . , , , .

, |

,

,

,

1

1. , , . , , . . . : 1) , , 2) , 3) - , , , , ., |

1: , , . . , . , , , , ,

1

. , , , 70% , 30% 3 .

2: , 5 6 , . . , a a je : Ca++ 10-x (H3O+) 2X (PO4) 6 (OH_) 2. , , , , , . 64 . . , , . . , , ( 2)., |

2

3: , , , , . , , ., |

, , . , , , , . 1, . , 1(IL1), (TNF), (PDGF), I, , , . , , , , , , , . , , . , , , ,

3

. , . . , , , . o-, , - . , . . 1% . . , , , . . , . , . 30 , 35 . 35 40 40 , 0,3 - 0,5% . , . ( . 3)

4: , . , , 2 - 5% , .

, |

4

2. , , . , . 20.000.000 $ . , , 8 10% . 30% , , , 40 50% .

. 95% , , ( 1). . . : , , . , , , , . , , , . . , , . . , , . .

, |

5

( ) ( ) : : : : 1: . 7,5 , 65 . , , , ., |

6

, , , , ( 4). , , , , . . . , (BMD) > 2,5 , (T-skor).

, |

5: . . , , . . , , , '' '' .

7

, , . . , 30% - , , , ( 6).

6: '' '' , , (DEXA) .

, , . , , . .

, |

8

, , , 40% , 25% , 12 - 20% , .

, , . . , . , . - : , . , , - , , , . .

, |

, , , . , .

1) 2) 3)

9

1. . , , , -2,5. , . , , . , , . . , 30 60 , . , . , . . , . . () . . 50%. . . , . . , . . , , . . , , . . , . .

10

, |

2. () . . 10-12% 60%. . , 2 20.

3. . . , . . . , , , ., |

.

, . . . . , . .

, . , . , .

11

1000. 1200 1500, 1500 2000, 1500 . , , , , , , , , , , , , , , . , , , , , , , , . 500 . - . . - . 50 200 IU, 50 400 IU, 70 600 IU. 200 IU. , , . .

7:

12

, |

. . , . , , , , , . , , . , , , , , , . , , . . , , . , , , . , , . . , , , ., |

13

3. I 48 , , . , . , , . : , , , , . -1,8 , . , . . , - -1,5 . : , ., |

II 62 , . . , . , , , , 150/95, , . - . , , . , . : CRP , , .

14

- L4-L5, L5-S1 . . , . - 4,37, -3,31 : . T -3.88 a -2,90 : , , , . , .

III 54 . , 15 , . , , . , . , , , , , . . . -. -1,9 , . 6 .

15

, |

4. GuytonAC, Hall JE, Textbook of Medical Physiology W B Saunders Co. 1996 Kohrt, W.M. et al. ACSM Position Stand: physical activity and bone health. Medicine andScience in Sports and Exercise, 36, pp.1985-1996. (2004). Baji, Z. i sar: Uticaj fizicke aktivnosti na kvalitet kosti; SportLogia 6 (2010) 1:7-13 Robins SL, Cotran RS, Cumar V :Pathologic basis of disease, 3rd ed Babic, Lj. (2004). Kalcijum, fosfor i metabolizam kosti, kalcijum regulisuci hormoni. U: Kulauzov, M. Patoloska fiziologija. Novi Sad: Medicinski fakultet i Futura. 2004. Skarica R, Potocki K: Radioloski atlas reumatskih bolesti, Medicinska knjiga Beograd 1989. E. Canalis, G. Mazziotti, A. Giustina, and J. P. Bilezikian, Glucocorticoid-induced osteoporosis: pathophysiology and therapy, Osteoporosis

International, vol. 18, no. 10, pp. 13191328, 2007. Burge RT, Dawson-Huges B, Solomon DH et all. Incidence and economic burden of osteoporosis related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22: 465-75. Silverman SL. Quality of life issues in osteoporosis. Curr Rheumatol Rep 2005; 7: 39-45. Brecki-Gisolf J, Hockey R, Dobson A. Adherence to bisphosphonate treatment by elderly women. Menopause 2008; 15: 984-90. Committee for Medicinal Products for Human Use (CHMP). Guideline on the Evaluation of new Medicinal Products in the Treatment of Primary Osteoporosis. CPMP/EWP/552/95 Rev. 2. European Medicines Agensy, London, 2005. Arabi A, Baddoura H, Awada H et al. Discriminative ability of dual energy X ray absorptiometry site selection in identifyng patient whit osteoporotic fractures. Bone 2007; 40: 1060-5, |

16